Frontier longevity science, fact-checked

This is the genuinely exciting end of longevity: partial reprogramming, senolytics that clear worn-out cells, young-blood plasma exchange, gene therapy, and the damage-repair vision behind SENS. Some of it is real, well-funded science with striking results in mice.

But frontier is the operative word. Almost all of it is mouse-stage or earlier, the human evidence ranges from thin to a single self-experiment, and some carries real risk (telomerase and cancer) or is sold through pay-to-play offshore clinics well ahead of the data. Our verdicts here range from Unproven (promising but untested in humans, like partial reprogramming and senolytics) to Unsupported (young-blood plasma exchange and the BioViva gene-therapy claim, where the human case does not hold up). Each linked check marks exactly how far along the evidence is.